Market capitalization | $9.73m |
Enterprise Value | $2.55m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.60 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.78m |
Free Cash Flow (TTM) Free Cash Flow | $-6.73m |
Cash position | $6.61m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast FSD Pharma Inc:
1 Analyst has issued a forecast FSD Pharma Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.50 -0.50 |
86%
86%
|
|
EBITDA | -11 -11 |
45%
45%
|
EBIT (Operating Income) EBIT | -12 -12 |
51%
51%
|
Net Profit | -10 -10 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for various central nervous system disorders, including chronic pain, fibromyalgia, and irritable bowel syndrome. FSD Pharma Inc. has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products; and collaborative research and development agreement with Solarvest BioEnergy Inc. The company is headquartered in Cobourg, Canada.
Head office | Canada |
CEO | Zeeshan Saeed |
Founded | 1994 |
Website | www.fsdpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.